– Invitae to report on secondary patient data
use, demonstrating real-world impact of de-identified patient data
on the advancement of precision medicine –
– Company achieves over 1 million ClinVar
submissions to advance science and patient care –
SAN
FRANCISCO, Dec. 7, 2022 /PRNewswire/ -- Invitae
(NYSE: NVTA), a leading medical genetics company, today announced
the release of its Data Use Transparency and Impact Report, which
details how the company has used de-identified patient data to
advance precision medicine. While many companies collect patient
data, they do not disclose how this data is being used. Invitae is
leading the industry by publishing this first-of-its-kind report on
how it used de-identified patient data for secondary data research
in 2021.
Unlike most companies, Invitae offers patients a choice on
whether or not to allow access to their de-identified data for
research. As a company grounded in the principles that patients own
and control their data and that data is more valuable when shared,
this report demonstrates how Invitae delivers on those principles
in a way that honors the intent of patients with the ultimate goal
of advancing the science of genomics and precision medicine.
"For precision medicine to advance and real-world evidence to
matter, patients must be able to trust that the companies accessing
and sharing their data are only working with trustworthy partners
who are equally committed to advancing science," said Deven McGraw, lead of data stewardship and data
sharing at Invitae. "Being transparent about how we use data is
essential to not only earning that trust but also to demonstrating
the impact that patients can have on advancing science and medicine
by sharing access to their data."
McGraw continued, "It's time for all companies that generate,
collect, use and share de-identified patient data to let patients
know how their data is being used and see the impact they are
having. In a culture of diminishing trust, transparency is no
longer an option. It's essential."
With a database of more than 2 million tested individuals around
the world which is available for researchers to access such
individuals' de-identified data, Invitae's research is critical to
understanding the prevalence of gene changes responsible for a wide
array of hereditary diseases, developing new treatments and
identifying people who could benefit from targeted, precision
therapies. In 2021, patient data enabled the company to advance
important research initiatives and achieve the following:
- Improving Internal Processes and Testing Quality:
Invitae uses the data generated by genetic testing to confirm our
tests meet applicable quality and validity standards, to ensure our
products improve, and to advance the science of genetic
testing.
- Advancing the Science of Genetics: De-identified data
from certain individuals tested by Invitae informed an array of
research across medical conditions, including contributions to 38
peer-reviewed publications across 10 health areas, 36 posters
covering 11 health topics and 21 abstracts as part of the
proceedings of more than 22 scientific symposia.
- Advancing the Development of New Treatments:
To help accelerate access to testing and the development and
use of genetic-informed therapies, Invitae offered
"sponsored" testing programs in which patients agree to allow
biopharma companies to access their de-identified data obtained
through no charge genetic testing. In 2021, Invitae
worked with 31 biopharma companies to offer 47 sponsored
testing programs. In addition, Invitae worked with 15
biopharma partners to conduct clinical trial outreach initiatives
covering 17 medical conditions.
- Advancing Science-Driven Policy: Based on analysis
of its test data, Invitae developed educational materials and
distributed them to policymakers considering the development of
legislation to expand access to pediatric genetic testing.
A New Milestone for Open Data
Further showcasing
the importance of sharing patient data, Invitae
recently reached a milestone of more than 1 million
ClinVar submissions. ClinVar is a National
Institutes of Health database of genetic variants that serves as a
global resource for sharing interpretations of different genetic
variants. ClinVar enables testing labs and researchers
to compare findings, helping to expand the collective understanding
of each variant. As the leading contributor to this
database, Invitae views this milestone as a testament
to the company's founding principle that genetic data is more
valuable when it's shared. Currently, Invitae has
contributed more variants than the next 16 largest contributors
to ClinVar combined.
"Patients need the science of genetics to advance as rapidly as
possible," said McGraw. "For that to happen, scientists need to
share the data that informs their interpretation with their peers.
This milestone shows we are committed to advancing the role that
genetic understanding can play in helping patients who need
treatments and cures."
"This first-of-its-kind report is an important first step
towards transparency, and it's something that should be standard
practice for the genetic diagnostic industry as a whole," said
Andrea Downing, co-founder of The
Light Collective. "Invitae is making important strides to lead the
industry in accountability to patient communities."
To learn more, you can download the full report
here.
About Invitae
Invitae Corporation (NYSE:
NVTA) is a leading medical genetics company, whose mission is
to bring comprehensive genetic information into mainstream medicine
to improve healthcare for billions of people. Invitae's
goal is to aggregate the world's genetic tests into a single
service with higher quality, faster turnaround time and lower
prices. For more information, visit the company's website at
invitae.com.
Safe Harbor Statement
This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to the company's belief that it is leading the
industry by publishing a first-of-its-kind report on how it used
de-identified, patient data for secondary data research; the
company's beliefs regarding the importance of this report and
transparency regarding data use; and the benefits of the company's
research and use of de-identified patient data. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially, and reported results should
not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: the
company's history of losses; the company's ability to compete; the
company's failure to manage growth effectively; the company's need
to scale its infrastructure in advance of demand for its tests and
to increase demand for its tests; the company's ability to use
rapidly changing genetic data to interpret test results accurately
and consistently; security breaches, loss of data and other
disruptions; laws and regulations applicable to the company's
business; and the other risks set forth in the company's filings
with the Securities and Exchange Commission, including the risks
set forth in the company's Quarterly Report on Form 10-Q for the
quarter ended September 30, 2022.
These forward-looking statements speak only as of the date hereof,
and Invitae Corporation disclaims any obligation to
update these forward-looking statements.
Contact:
Renee
Kelley
pr@invitae.com
(628)
213-3283
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invitae-releases-data-use-transparency-report-demonstrating-the-impact-of-patient-data-on-genetic-research-301696210.html
SOURCE Invitae Corporation